Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA
SHENZHEN, China, May 29, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed...
May 19: World Inflammatory Bowel Disease Day | Healthy Gut, Happy Life
SHENZHEN, China, May 26, 2025 /PRNewswire/ -- May 19 is designated as World Inflammatory Bowel Disease (IBD) Day, aimed at raising public awareness of IBD patients and improving their quality of life and medical care. The European Federation of...
Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by...
Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention
SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference in San Francisco and the Global Biopharma...